Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma

NCT04757662 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04757662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04757662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study to Use Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2021
Completion date
June 7, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iii, astrocytoma, grade iv, grade iii astrocytoma, grade iv astrocytoma